Sonoma Pharmaceuticals EPS Ratio 2011-2026 | SNOA

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares^[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Sonoma Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-2.79	-10.6	-1.52	-1.92	-1.97	-2.24	-12.8	-28.5	2.2	-3.09	-0.85	0.54	-1.3	-1.87	-0.3

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.2	-28.5	-4.47

Quarterly EPS Ratio Sonoma Pharmaceuticals

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-0.48	-0.32	-0.76	-	-0.63	-0.59	-1.34	-	-1.59	-5.75	-0.29	-	-0.62	-0.33	-0.29	-	-0.31	-0.85	-0.54	-	-0.32	-0.32	0.06	0.13	-0.72	-0.92	0.54	0.54	-0.26	-1.2	-0.99	-	-0.73	-0.67	-0.82	-	3.84	2.79	-1.08	-	-0.96	-2.27	-1.3	-	-0.69	-0.79	-0.09	-	-0.09	-0.56	-0.47	-	-0.37	-0.85	-0.47	-	-0.09	-0.21	-0.11	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
3.84	-5.75	-0.514

References

Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Drug manufacturers industry

Issuer	EPS Ratio	Price	% 24h	Market Cap	Country
Assertio Holdings ASRT	-4.74	$ 18.05	0.17 %	$ 116 M	USA
Agile Therapeutics AGRX	-6.71	-	10.11 %	$ 58.2 M	USA
AcelRx Pharmaceuticals ACRX	-0.34	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	-0.18	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-1.61	-	-	$ 754 M	USA
Catalent CTLT	-5.76	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	-1.05	-	-	$ 50.1 M	USA
Alimera Sciences ALIM	-0.84	-	-	$ 142 M	USA
Athenex ATNX	-15.8	-	-23.39 %	$ 1.76 M	USA
Eagle Pharmaceuticals EGRX	2.76	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	-10.4	-	-	$ 28.9 M	Irlanda
Avadel Pharmaceuticals plc AVDL	-0.51	-	-	$ 2.06 B	France
Evoke Pharma EVOK	-2.33	-	-	$ 36.6 M	USA
Cumberland Pharmaceuticals CPIX	-0.14	$ 3.15	1.94 %	$ 44.3 M	USA
Calliditas Therapeutics AB (publ) CALT	-9.66	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	-0.89	-	2.45 %	$ 38.1 M	Canada
Bausch Health Companies BHC	-1.62	$ 5.58	-0.53 %	$ 2.04 B	Canada
Harrow Health HROW	-0.14	$ 36.02	0.25 %	$ 1.32 B	USA
Aurora Cannabis ACB	-4.1	$ 3.33	-2.99 %	$ 86.3 M	Canada
Canopy Growth Corporation CGC	-5.56	$ 1.03	-1.92 %	$ 111 M	Canada
OrganiGram Holdings OGI	-0.51	$ 1.38	-1.44 %	$ 402 M	Canada
Neoleukin Therapeutics NLTX	-4.24	-	-	$ 193 M	Canada
Jupiter Wellness JUPW	-17	-	-	$ 33.6 M	USA
Relmada Therapeutics RLMD	-1.45	$ 7.32	0.34 %	$ 289 M	USA
Lannett Company LCI	-5.74	-	1.15 %	$ 7.11 M	USA
Evolus EOLS	-0.8	$ 4.31	0.94 %	$ 278 M	USA
Emergent BioSolutions EBS	-14.8	$ 7.9	-0.75 %	$ 404 M	USA
Sundial Growers SNDL	-1.1	$ 1.37	-3.52 %	$ 3.37 M	Canada
Tilray TLRY	-2.35	$ 6.4	-2.59 %	$ 3.96 B	Canada
Organogenesis Holdings ORGO	-0.01	$ 2.35	-1.26 %	$ 309 M	USA
Pacira BioSciences PCRX	-2.15	$ 23.71	-0.34 %	$ 1.1 B	USA
PetIQ PETQ	0.07	-	1.64 %	$ 400 M	USA
Veru VERU	-0.28	$ 2.4	0.84 %	$ 324 M	USA
Viatris VTRS	0.05	$ 13.43	-0.33 %	$ 16.1 B	USA
ProPhase Labs PRPH	1.17	-	-	$ 5.07 M	USA
cbdMD YCBD	-1.79	$ 0.66	-2.96 %	$ 2.85 M	USA
Radius Health RDUS	-1.49	-	-	$ 1.42 B	USA
Recro Pharma REPH	-0.14	-	-4.76 %	$ 65.3 M	USA
OptiNose OPTN	-0.32	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	-0.17	$ 1.0	-	$ 49.9 M	USA
PLx Pharma PLXP	-2.06	-	-27.8 %	$ 2.56 M	USA
Solid Biosciences SLDB	-1.99	$ 7.87	-1.87 %	$ 689 M	USA
Zomedica Corp. ZOM	-0.08	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	-0.82	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	-0.15	$ 0.91	-0.02 %	$ 32.7 M	USA
Tricida TCDA	-3.44	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	-0.74	$ 0.63	-	$ 2.7 M	China
TherapeuticsMD TXMD	-0.05	$ 2.13	3.14 %	$ 24.6 M	USA